Top news of the week: 22.09.2020.
#coronavirus #clinicaltrials #treatment #biotechnology #vaccine #COVID19 #COVID #biospace #lifesciences #pharmaceuticals
Companies And Industries
The Dish’s Weekly Biotechnology News Wrap Up – September 18, 2020
This week's headlines include: GenSight Biologics seeks EU approval for gene therapy, Lonza works with Humanigen on COVID-19 drug candidate lenzilumab, Univercells Introduces NevoLine ...
Biopharma Update on the Novel Coronavirus: September 16
#biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine
https://t.co/TzgAgXaYiW
OpenBiopharma Update on the Novel Coronavirus: September 16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
RT @PearlF: "Anti-aging" and "longevity" biotech Unity is cutting 30% of its staff to restructure & transition to focus on ophthalmology and neurology. Story by @nicole_defaudis https://t.co/AlhC7CdXm9
OpenA month after losing its lead program, Unity Biotechnology cuts 30% of staff in restructuring
Unity Biotechnology's lead anti-aging program faced the chopping block last month following a major Phase II flop. And now, 30% of its staff are next, as the company restructures to focus ...
.@Moderna_tx signs R&D deals worth $100m upfront with @VertexPharma and #Chiesi Farmaceutici, focusing on drugs for cystic fibrosis and pulmonary arterial hypertension https://t.co/jbOmpNPMXA https://t.co/ePA65Yss0Q
OpenModerna broadens R&D scope with Vertex, Chiesi alliances
Moderna signs R&D deals worth $100m upfront with Vertex and Chiesi Farmaceutici, focused on drugs for cystic fibrosis and pulmonary arterial hypertension
Biopharma Update on the Novel Coronavirus: September 18
#biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine
https://t.co/VRIGtG4BfN
OpenBiopharma Update on the Novel Coronavirus: September 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
Biopharma Update on the Novel Coronavirus: September 21
#biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine
https://t.co/etPvr5oiws
OpenBiopharma Update on the Novel Coronavirus: September 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
MPM, which lists Pharmasset and Semma Therapeutics among its exits, has identified Roden as a good fit for its push to create a team capable of supporting its biotech-building program. https://t.co/iASbSCZlFU
OpenRoden, fresh from BMS-Celgene merger, lands VC role at MPM
MPM Capital has hired Matthew Roden as executive partner. The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build ...
Agilent Technologies is pleased to bring you the Biopharma Workflow Symposium: Advances in Glycan and Sialic Acid Analysis, Sept 22, 2020. This one-day virtual event aims to serve as a platform to bring the biopharma community together. Register here: https://t.co/7xr1J4v7RM https://t.co/RYFCK03sWA
OpenAgilent Biopharma Workflow Solutions Virtual Symposium: Advances in Glycan and Sialic Acid Analysis
Agilent Technologies is pleased to bring you the Agilent Biopharma Workflow Solutions Virtual Symposium: Advances in Glycan and Sialic Acid Analysis